Medindia LOGIN REGISTER
Medindia
Advertisement

Genetic Mutation Key for Targeted Lung Cancer Therapy, Not Smoking History

by Anjali Aryamvally on December 14, 2017 at 12:56 PM
Genetic Mutation Key for Targeted Lung Cancer Therapy, Not Smoking History

Smokers are less likely than non-smokers to have lung cancers caused by targetable genetic changes. But a study published in the journal Clinical Cancer Research shows that when they do, smokers benefit just as much as non-smokers from targeted treatments.

"A smoker or former smoker with a targetable alteration has the same probability of benefitting from targeted therapy as a never-smoker with a targetable alteration," says Dara Aisner, PhD, investigator at the University of Colorado Cancer Center and molecular pathologist at CU School of Medicine.

Advertisement


Aisner participated in the study as a member of the Lung Cancer Mutation Consortium (LCMC), a group of 16 research institutions collaborating to explore the genetic drivers of lung cancer. Over the course of data collection, the LCMC enrolled 1,367 lung cancer patients, of which 904 had testing for at least one of 14 cancer-related genes. The current study explored the outcomes of smokers and non-smokers who were treated with targeted therapies against EGFR, ALK, or ROS1.

No matter a patient's smoking history, when one of these targetable genetic alterations was present, matching the alteration with the appropriate targeted therapy was associated with a survival benefit of 1.5 years, compared with patients (smokers and non-smokers) without these alterations.
Advertisement

"Historically, the recommendations have always said that you shouldn't use someone's smoking history to decide whether that person's lung cancer should receive broad molecular profiling. This strengthens the science behind those recommendations," Aisner says.

Aisner also points out that not every patient - smoking or non-smoking - will see this benefit from targeted treatments. Regardless of smoking status, some patients will see little benefit, while others may see much more benefit than the average 1.5 years increase over patients who do not receive targeted therapies.

While smokers with targetable genetic changes are equally likely to benefit from targeted treatments, their cancers are less likely to hold these changes. KRAS is the most commonly mutated gene in lung cancer patients with smoking history, found in about 30-40 percent of these cases. Unfortunately, KRAS mutation is currently without an effective targeted treatment. However, KRAS mutation is found in only 6 percent of non-smoking lung cancer patients.

This means that doctors are less likely to find actionable targets when genetically testing a smoker's lung cancer than they are when testing a non-smoker's cancer. It is an open question whether this may bias oncologists against offering genetic testing to lung cancer patients who smoke, despite the fact that guidelines recommend genetic testing regardless of smoking history.

"To my knowledge, nobody's ever looked at whether smokers who have a targetable alteration do as well as non-smokers with these alterations. You might think that comorbidities and other lifestyle factors that tend to accompany smoking might make it seem as if they do less well on these therapies, but our data show that's not the case," Aisner says.

"Essentially, no matter if you do or do not smoke, if your lung cancer holds a targetable alteration, you have the same chance of benefitting from targeted treatments," Aisner says.



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cancer News

How CAR-T Cell Therapy is Effective For Lymphoma in Remission?
CAR-T immunotherapy is a viable treatment option for individuals whose lymphoma enters remission before beginning cell therapy.
Disease-Free Outcomes in Breast Cancer Patients
Study reveals five years of disease-freedom among postmenopausal patients aged 50-69, diagnosed with breast cancer.
A Sweat for Health: Exercise Benefits Breast Cancer Patients
Engaging in regular exercise could significantly enhance the quality of life for individuals facing metastatic breast cancer.
Diabetes Drug Tied to Lowered Colorectal Cancer Risk
Drugs known as glucagon-like peptide-1 receptor agonists, prescribed for type 2 diabetes, could lower the likelihood of developing colorectal cancer.
Anti-allergy Drug Dupilumab Treats Lung Cancer
Researchers found a pathway linked to allergies that, when blocked, triggers antitumor immunity in lung cancer mouse models.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

Genetic Mutation Key for Targeted Lung Cancer Therapy, Not Smoking History Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests